Welcome to our dedicated page for Definium Therapeutics SEC filings (Ticker: DFTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Definium Therapeutics, Inc. (DFTX) SEC filings page on Stock Titan is designed to help readers review the company’s regulatory disclosures in one place. While no specific filings are listed in the provided data, Definium references documents such as its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q in its public communications, indicating that it files reports with the U.S. Securities and Exchange Commission.
Stock Titan connects to the SEC’s EDGAR system so that when Definium Therapeutics submits new filings, they can be displayed with AI-generated summaries. These summaries are intended to highlight key themes in lengthy documents, such as risk factor discussions, updates on the company’s psychiatric and neurological drug pipeline, and commentary on clinical study progress for candidates like DT120 ODT and DT402 as described in the company’s public statements.
For investors and researchers, this page can provide access to core filing types, including annual reports on Form 10-K and quarterly reports on Form 10-Q, once available. It can also surface other filing categories that may be relevant over time, such as registration statements or current reports, which often discuss material events, clinical milestones, or capital-raising activities referenced in the company’s forward-looking disclosures.
In addition to listing documents as they are filed, Stock Titan’s AI tools can help explain complex regulatory language in more accessible terms. This can be useful when reviewing sections that discuss Definium Therapeutics’ focus on psychedelic-inspired psychiatry, its clinical trial programs in generalized anxiety disorder, major depressive disorder, and autism spectrum disorder, and the risks and uncertainties the company highlights in its own cautionary statements.
Definium Therapeutics, Inc. reported that Chief Executive Officer and director Robert Barrow received an award of 320,000 restricted stock units (RSUs)June 1, 2026. After this grant, Barrow beneficially owns 1,098,477 common shares of Definium Therapeutics.
Definium Therapeutics director Roger Adsett received a grant of stock options on 01/29/2026. The award covers options to buy 50,000 common shares at an exercise price of $17.24 per share, all held directly.
The options vest over three years, with one-third vesting on the first anniversary of the grant date and the remaining two-thirds vesting in 24 equal monthly installments, contingent on Mr. Adsett’s continued service to the company.
Definium Therapeutics director reports no holdings
Definium Therapeutics, Inc. director Roger Adsett filed an initial ownership report stating that he does not beneficially own any Definium Therapeutics securities. The filing is administrative in nature and does not describe any stock purchases, sales, or other transactions.
Definium Therapeutics, Inc. reported a change to its board of directors. On January 28, 2026, the board expanded from six to seven members and appointed Roger Adsett as a director effective January 29, 2026, with a term running until the 2026 annual general meeting, or until a successor is chosen or he departs earlier.
Adsett was not assigned to any board committees at this time. Under the company’s non-employee director compensation policy, he will receive an annual cash retainer of $40,000, paid quarterly on a pro-rata basis. He also received an option to purchase 50,000 common shares, vesting one-third on the first anniversary of the grant date and the remainder in equal monthly installments thereafter, subject to continued board service.
The option grant was issued under the company’s 2025 Equity Incentive Plan. The filing notes there are no special arrangements leading to his appointment and no related-party transactions requiring disclosure under Item 404(a) of Regulation S-K.